

**Maryse LAPEYRE-MESTRE** - Publications 2015-2019

Equipe émergente - Pharmaco-épidémiologie, évaluation de l'utilisation et du risque médicamenteux

Equipe émergente : Pharmaco-épidémiologie, évaluation de l'utilisation et du risque médicamenteux

*Articles dans des revues internationales ou nationales avec comité de lecture ou dans les bases de données internationales* *Mise à jour juillet 2019*

---

2019

1. Carr DF, Francis B, Jorgensen AL, Zhang E, Chinoy H, Heckbert SR, Bis JC, Brody JA, Floyd J, Psaty BM, Molokhia M, **Lapeyre-Mestre M**, Conforti A, Alfirovic A, van Staa T, Pirmohamed M. [Genome-wide association study of statin-induced myopathy in patients recruited using the UK clinical practice research datalink](#). Clin Pharmacol Ther. 2019 Jun 20. doi: 10.1002/cpt.1557. [Epub ahead of print]
2. Caudrelier L, Moulis G, **Lapeyre-Mestre M**, Sailler L, Pugnet G. [Validation of giant cell arteritis diagnosis code in the French hospital electronic database](#). Eur J Intern Med. 2019 Feb;60:e16-e17. doi: 10.1016/j.ejim.2018.10.004.
3. Conte C, Bourrel R, Despas F, **Lapeyre-Mestre M**. [Is there overuse of proton pump inhibitors in B-cell non-Hodgkin lymphomas? A cohort study based on the French health insurance database in the Midi-Pyrénées region](#). Fundam Clin Pharmacol. 2019 Jun;33(3):327-338. doi: 10.1111/fcp.12436.
4. Conte C, Vaysse C, Bosco P, Noize P, Fourrier-Reglat A, Despas F, **Lapeyre-Mestre M**. [The value of a health insurance database to conduct pharmacoepidemiological studies in oncology](#). Therapie. 2019 Apr;74(2):279-288. doi: 10.1016/j.therap.2018.09.076.
5. Coutens B, Mouledous L, Stella M, Rampon C, **Lapeyre-Mestre M**, Roussin A, Guiard BP, Jouanjus E. [Lack of correlation between the activity of the mesolimbic dopaminergic system and the rewarding properties of pregabalin in mouse](#). Psychopharmacology (Berl). 2019 Mar 16. doi: 10.1007/s00213-019-05198-z. [Epub ahead of print]
6. de Germay S, Rueter M, Montastruc F, Rousseau V, **Lapeyre-Mestre M**, Montastruc JL. [Trends of atropinic \(anticholinergic\) exposure in the elderly: a 10-year analysis in the French EGB database](#). Fundam Clin Pharmacol. 2019 Aug;33(4):471-478. doi: 10.1111/fcp.12450.
7. Driot D, Jouanjus E, Oustric S, Dupouy J, **Lapeyre-Mestre M**. [Patterns of gabapentin and pregabalin use and misuse: Results of a population-based cohort study in France](#). Br J Clin Pharmacol. 2019 Jun;85(6):1260-1269. doi: 10.1111/bcp.13892.
8. Dupui M, Micallef J, **Lapeyre-Mestre M**. [Interest of large electronic health care databases in addictovigilance: Lessons from 15 years of pharmacoepidemiological contribution](#). Therapie. 2019 Apr;74(2):307-314. doi: 10.1016/j.therap.2018.09.078.
9. Ekstrand C, Linder M, Baricault B, Lafaurie M, Sailler L, **Lapeyre-Mestre M**, Kieler H, Moulis G, Bahmanyar S. [Impact of risk factors on the occurrence of arterial thrombosis and venous thromboembolism in adults with primary immune thrombocytopenia - Results from two nationwide cohorts](#). Thromb Res. 2019 Jun;178:124-131. doi: 10.1016/j.thromres.2019.04.016.
10. Floyd JS, Bloch KM, Brody JA, Maroteau C, Siddiqui MK, Gregory R, Carr DF, Molokhia M, Liu X, Bis JC, Ahmed A, Liu X, Hallberg P, Yue QY, Magnusson PKE, Brisson D, Wiggins KL, Morrison AC, Khoury E, McKeigue P, Stricker BH, **Lapeyre-Mestre M**, Heckbert SR, Gallagher AM, Chinoy H, Gibbs RA, Bondon-Guitton E, Tracy R, Boerwinkle E, Gaudet D, Conforti A, van Staa T, Sitlani CM, Rice KM, Maitland-van

*UMR1027 - Equipe émergente - Maryse Lapeyre-Mestre - Publications 2015-2019*

der Zee AH, Wadelius M, Morris AP, Pirmohamed M, Palmer CAN, Psaty BM, Alfirevic A; PREDICTION-ADR Consortium and EUDRAGENE. [Pharmacogenomics of statin-related myopathy: Meta-analysis of rare variants from whole-exome sequencing](#). PLoS One. 2019 Jun 26;14(6):e0218115. doi: 10.1371/journal.pone.0218115.

11. Franchini DM, Lanvin O, Tosolini M, Patras de Campaigno E, Cammas A, Péricart S, Scarlata CM, Lebras M, Rossi C, Ligat L, Pont F, Arimondo PB, Laurent C, Ayyoub M, Despas F, **Lapeyre-Mestre M**, Millevoi S, Fournié JJ. [Microtubule-Driven Stress Granule Dynamics Regulate Inhibitory Immune Checkpoint Expression in T Cells](#). Cell Rep. 2019 Jan 2;26(1):94-107.e7. doi: 10.1016/j.celrep.2018.12.014.
12. Jouanjus E, Micallef J, Mallaret M, **Lapeyre-Mestre M**; French Addictovigilance Network. [Generalizing the use of a multidimensional approach to move towards an effective Addictovigilance](#). Int J Neuropsychopharmacol. 2019 Jun 13. pii: pyz033. doi: 10.1093/ijnp/pyz033. [Epub ahead of print]
13. **Lapeyre-Mestre M**, Montastruc F. [Interest of pharmacoepidemiology for pharmacodynamics and analysis of the mechanism of action of drugs](#). Therapie. 2019 Apr;74(2):209-214. doi: 10.1016/j.therap.2018.12.010.
14. **Lapeyre-Mestre M**. [Benzodiazepines, cognitive decline and dementia: A review of causality criteria from published observational studies](#). Therapie. 2019 Jun;74(3):407-419. doi: 10.1016/j.therap.2018.09.071.
15. Montastruc JL, Benevent J, Montastruc F, Bagheri H, Despas F, **Lapeyre-Mestre M**, Sommet A. [What is pharmacoepidemiology? Definition, methods, interest and clinical applications](#). Therapie. 2019 Apr;74(2):169-174. doi: 10.1016/j.therap.2018.08.001.
16. Ponté C, Giron A, Crequy M, **Lapeyre-Mestre M**, Fabre N, Salles J. [Cluster Headache in Subjects With Substance Use Disorder: A Case Series and a Review of the Literature](#). Headache. 2019 Apr;59(4):576-589. doi: 10.1111/head.13516.
17. Walburg V, Rueter M, Lamy S, Compaci G, **Lapeyre-Mestre M**, Laurent G, Despas F. [Fear of cancer recurrence in Non- and Hodgkin lymphoma survivors during their first three years of survivorship among French patients](#). Psychol Health Med. 2019 Aug;24(7):781-787. doi: 10.1080/13548506.2019.1574354.

## 2018

1. Conte C, Palmaro A, Grosclaude P, Daubisse-Marliac L, Despas F, **Lapeyre-Mestre M**. [A novel approach for medical research on lymphomas: A study validation of claims-based algorithms to identify incident cases](#). Medicine (Baltimore). 2018 Jan;97(2):e9418. doi: 10.1097/MD.00000000000009418.
2. Cool C, Cestac P, McCambridge C, Rouch L, de Souto Barreto P, Rolland Y, **Lapeyre-Mestre M**. [Reducing potentially inappropriate drug prescribing in nursing home residents: effectiveness of a geriatric intervention](#). Br J Clin Pharmacol. 2018 Jul;84(7):1598-1610. doi: 10.1111/bcp.13598.
3. Couderc S, **Lapeyre-Mestre M**, Bourrel R, Paul C, Montastruc JL, Sommet A. [Infectious risk of biological drugs vs. traditional systemic treatments in moderate-to-severe psoriasis: a cohort analysis in the French insurance database](#). Fundam Clin Pharmacol. 2018 Aug;32(4):436-449. doi: 10.1111/fcp.12358.
4. Daveluy A, Sauvaget L, Bastien A, **Lapeyre-Mestre M**, Collin C, Richard N, Haramburu F. [Tamper-resistant prescription forms for narcotics in France: Should we generalize them?](#) Fundam Clin Pharmacol. 2018 Oct;32(5):571-577. doi: 10.1111/fcp.12368.
5. de Germay S, **Lapeyre-Mestre M**, Montastruc JL, Montastruc F. [Atropinic burden and anticholinergic drugs: Interest and application in clinical practice in the elderly](#). Therapie. 2018 Mar 7. pii: S0040-5957(18)30043-X. doi: 10.1016/j.therap.2018.02.010. [Epub ahead of print]

6. Essilini A, Comont T, Germain J, Brun N, Dingremont C, Castel B, Arista S, Madaule S, Sailler L, **Lapeyre-Mestre M.**, Beyne-Rauzy O, Godeau B, Adoue D, Moulis G; CARMEN investigators group. [Pretreatment with standard-dose intravenous methylprednisolone does not improve outcomes in newly diagnosed immune thrombocytopenia \(ITP\)](#). Eur J Haematol. 2018 May;100(5):412-418. doi: 10.1111/ejh.13032.
7. Fuzier R, Serres I, Bourrel R, Palmaro A, **Lapeyre-Mestre M.** [Analgesic Drug Prescription After Carpal Tunnel Surgery: A Pharmacoepidemiological Study Investigating Postoperative Pain](#). Reg Anesth Pain Med. 2018 Jan;43(1):19-24. doi: 10.1097/AAP.0000000000000685.
8. Jouanjus E, Falcou A, Deheul S, Roussin A, **Lapeyre-Mestre M.** [Detecting the diverted use of psychoactive drugs by adolescents and young adults: A pilot study](#). Pharmacoepidemiol Drug Saf. 2018 Nov;27(11):1286-1292. doi: 10.1002/pds.4624.
9. Jouanjus E, Guernec G, **Lapeyre-Mestre M.**; French Addictovigilance Network. [Medical prescriptions falsified by the patients: a 12-year national monitoring to assess prescription drug diversion](#). Fundam Clin Pharmacol. 2018 Jun;32(3):306-322. doi: 10.1111/fcp.12356.
10. Kaguelidou F, Sommet A, **Lapeyre-Mestre M.** [Use of French healthcare insurance databases in pediatric pharmacoepidemiology](#). Therapie. 2018 Apr;73(2):127-133. doi: 10.1016/j.therap.2017.11.008.
11. Lafaurie M, Pochard L, Lotiron C, Molinier L, **Lapeyre-Mestre M.**, Jouanjus E. [Identification of Somatic Disorders Related to Psychoactive Drug Use from an Inpatient Database in a French University Hospital](#). Clin Drug Investig. 2018 Oct;38(10):977-982. doi: 10.1007/s40261-018-0679-4.
12. **Lapeyre-Mestre M.** [Identification and tracking of addictovigilance signals in general practice: which interactions between the general practitioners and the French addictovigilance network?](#) Fundam Clin Pharmacol. 2018 Dec;32(6):641-642. doi: 10.1111/fcp.12425.
13. Montastruc F, Bagheri H, Lacroix I, Damase-Michel C, Chebane L, Rousseau V, Jouanjus E, **Lapeyre-Mestre M.**, Durrieu G, Montastruc JL. [Adverse Drug Reaction Reports Received Through the Mobile App, VigiBIP®: A Comparison with Classical Methods of Reporting](#). Drug Saf. 2018 May;41(5):511-514. doi: 10.1007/s40264-017-0630-2.
14. Montastruc F, Bagheri H, Lacroix I, Damase-Michel C, Chebane L, Rousseau V, Jouanjus E, **Lapeyre-Mestre M.**, Durrieu G, Montastruc JL. [Adverse Drug Reaction Reports Received Through the Mobile App, VigiBIP®: A Comparison with Classical Methods of Reporting](#). Drug Saf. 2018 May;41(5):511-514. doi: 10.1007/s40264-017-0630-2.
15. Montastruc F, Khosrow-Khavar F, de Germay S, Renoux C, Rousseau V, Durrieu G, Montastruc M, Rascol O, Sommet A, **Lapeyre-Mestre M.**, Benevent J, Montastruc JL. [Tamoxifen and the risk of Parkinsonism: a case/non-case study](#). Eur J Clin Pharmacol. 2018 Sep;74(9):1181-1184. doi: 10.1007/s00228-018-2496-3.
16. Moulis G, Durrieu G, **Lapeyre-Mestre M.** [Off-label and unlicensed drug use in children population](#). Therapie. 2018 Apr;73(2):135-149. doi: 10.1016/j.therap.2018.02.002.
17. Moulis G, Germain J, Comont T, Arrouy A, **Lapeyre-Mestre M.**, Adoue D; CARMEN investigators group. [Cardiovascular risk factors in immune thrombocytopenia adults: Results from the CARMEN registry](#). Am J Hematol. 2018 Jul;93(7):E181-E184. doi: 10.1002/ajh.25127.
18. Moulis G, Ibañez B, Palmaro A, Aizpuru F, Millan E, **Lapeyre-Mestre M.**, Sailler L, Cambra K. [Cross-national health care database utilization between Spain and France: results from the EPICHRONIC study assessing the prevalence of type 2 diabetes mellitus](#). Clin Epidemiol. 2018 Jul 27;10:863-874. doi: 10.2147/CLEP.S151890.

19. Moulis G, **Lapeyre-Mestre M**. [\[Propensity score: Interests, use and limitations. A practical guide for clinicians\]](#). Rev Med Interne. 2018 Oct;39(10):805-812. doi: 10.1016/j.revmed.2018.02.012.
20. Moulis G, Pugnet G, Costedoat-Chalumeau N, Mathian A, Leroux G, Boutémy J, Espitia O, Bouillet L, Berthier S, Gaultier JB, Jeandel PY, Konaté A, Mékinian A, Solau-Gervais E, Terrier B, Wendling D, Andry F, Garnier C, Cathébras P, Arnaud L, Palmaro A, Cacoub P, Amoura Z, Piette JC, Arlet P, **Lapeyre-Mestre M**, Sailler L. [Efficacy and safety of biologics in relapsing polycondritis: a French national multicentre study](#). Ann Rheum Dis. 2018 Mar 13. pii: annrheumdis-2017-212705. doi: 10.1136/annrheumdis-2017-212705.
21. Mounié M, Costa N, Sailler L, **Lapeyre-Mestre M**, Bourrel R, Savy N, Molinier L, Pugnet G. [Incremental Costs in Giant Cell Arteritis](#). Arthritis Care Res (Hoboken). 2018 Jul;70(7):1074-1081. doi: 10.1002/acr.23429.
22. Mounié M, Pugnet G, Savy N, **Lapeyre-Mestre M**, Molinier L, Costa N. [Additional Costs of Polymyalgia Rheumatica With Giant Cell Arteritis](#). Arthritis Care Res (Hoboken). 2018 Aug 29. doi: 10.1002/acr.23736. [Epub ahead of print]
23. Patras de Campaigno E, Kebir I, Montastruc JL, Rueter M, Maret D, **Lapeyre-Mestre M**, Sallerin B, Despas F. [Correction to: Drug-Induced Dental Caries: A Disproportionality Analysis Using Data from VigiBase](#). Drug Saf. 2018 Aug;41(8):827. doi: 10.1007/s40264-018-0672-0.
24. Piel-Julian ML, Mahévas M, Germain J, Languille L, Comont T, **Lapeyre-Mestre M**, Payrastre B, Beyne-Rauzy O, Michel M, Godeau B, Adoue D, Moulis G; CARMEN investigators group. [Risk factors for bleeding, including platelet count threshold, in newly diagnosed immune thrombocytopenia adults](#). J Thromb Haemost. 2018 Sep;16(9):1830-1842. doi: 10.1111/jth.14227.
25. Pochard L, Dupouy J, Frauger E, Giocanti A, Micallef J, **Lapeyre-Mestre M**; French Addictovigilance Network. [Impact of pregnancy on psychoactive substance use among women with substance use disorders recruited in addiction specialized care centers in France](#). Fundam Clin Pharmacol. 2018 Apr;32(2):188-197. doi: 10.1111/fcp.12346.
26. Ponté C, Lepelley M, Boucherie Q, Mallaret M, **Lapeyre Mest** M, Pradel V, Micallef J. [Doctor shopping of opioid analgesics relative to benzodiazepines: A pharmacoepidemiological study among 11.7 million inhabitants in the French countries](#). Drug Alcohol Depend. 2018 Jun 1;187:88-94. doi: 10.1016/j.drugalcdep.2018.01.036.
27. Prat M, Derumeaux H, Sailler L, **Lapeyre-Mestre M**, Moulis G. [Positive predictive values of peripheral arterial and venous thrombosis codes in French hospital database](#). Fundam Clin Pharmacol. 2018 Feb;32(1):108-113. doi: 10.1111/fcp.12326.
28. Revet A, Montastruc F, Raynaud JP, Baricault B, Montastruc JL, **Lapeyre-Mestre M**. [Trends and Patterns of Antidepressant Use in French Children and Adolescents From 2009 to 2016: A Population-Based Study in the French Health Insurance Database](#). J Clin Psychopharmacol. 2018 Aug;38(4):327-335. doi: 10.1097/JCP.0000000000000891.
29. Rioufol C, Lamy S, Conte C, Jeanneau P, Compaci G, Delpierre C, **Lapeyre-Mestre M**, Laurent G, Despas F. [Non-cancer drug consumption during the early trajectory of lymphoma survivorship](#). Therapie. 2018 Sep;73(4):307-317. doi: 10.1016/j.therap.2017.10.007.
30. Rwagitivitywa J, **Lapeyre-Mestre M**, Bourrel R, Montastruc JL, Sommet A. [Comparison of adherence to generic multi-tablet regimens vs. brand multi-tablet and brand single-tablet regimens likely to incorporate generic antiretroviral drugs by breaking or not fixed-dose combinations in HIV-infected patients](#). Fundam Clin Pharmacol. 2018 Aug;32(4):450-458. doi: 10.1111/fcp.12363.

31. Rwagitinywa J, **Lapeyre-Mestre M**, Bourrel R, Sommet A. [Generic antiretroviral drug use in HIV-infected patients: A cohort study from the French health insurance database](#). *Therapie*. 2018 May - Jun;73(3):257-266. doi: 10.1016/j.therap.2017.10.001.
32. Rwagitinywa J, Sommet A, Palmaro A, Montastruc JL, **Lapeyre-Mestre M**. [Utilization and costs of HIV antiretroviral drugs in Europe during the last ten years: Impact of generic antiretroviral drugs on cost reduction](#).
33. Verga-Gérard A; Le groupe Soins primaires du réseau Recherche en épidémiologie clinique et en santé publique (RECaP); Le groupe Soins primaires du réseau Recherche en épidémiologie clinique et en santé publique (RECaP). (**Lapeyre-Mestre M** collaborator) [\[Primary care: A definition of the field to develop research\]](#). *Rev Epidemiol Sante Publique*. 2018 Mar;66(2):157-162. doi: 10.1016/j.respe.2017.09.004.

#### 2017

1. Caillet C, Sichanh C, Assemat G, Malet-Martino M, Sommet A, Bagheri H, Sengxeu N, Mongkhonmath N, Mayxay M, Syhakhang L, **Lapeyre-Mestre M**, Newton PN, Roussin A. [Role of Medicines of Unknown Identity in Adverse Drug Reaction-Related Hospitalizations in Developing Countries: Evidence from a Cross-Sectional Study in a Teaching Hospital in the Lao People's Democratic Republic](#). *Drug Saf*. 2017 May 20. doi: 10.1007/s40264-017-0544-z.
2. Casaurancq MC, Campaigno EP, Rueter M, Baricault B, Bourrel R, **Lapeyre-Mestre M**, Sommet A. [\[Outpatient consumption of antibiotics with a bacterial resistance risk in 2014 in France\]](#). *Therapie*. 2017 May 26. pii: S0040-5957(17)30084-7. doi: 10.1016/j.therap.2017.03.002.
3. Dupouy J, **Lapeyre-Mestre M**, Oustric S. [Psychiatric disorders as predictors of long-term opioid therapy and the need for treating chronic pain correctly in patients with prior opioid substance use disorder: a commentary](#). *Pain*. 2017 Jan;158(1):6-7.
4. Dupouy J, Palmaro A, Fatséas M, Auriacombe M, Micallef J, Oustric S, **Lapeyre-Mestre M**. [Mortality Associated With Time in and Out of Buprenorphine Treatment in French Office-Based General Practice: A 7-Year Cohort Study](#). *Ann Fam Med*. 2017 Jul;15(4):355-358. doi: 10.1370/afm.2098.
5. Gallini A, Coley N, Andrieu S, **Lapeyre-Mestre M**, Gardette V. [Effect of dementia on receipt of influenza vaccine: a cohort study in French older adults using administrative data: 2007-2012](#). *Fundam Clin Pharmacol*. 2017 Aug;31(4):471-480. doi: 10.1111/fcp.12281.
6. Jouanjus E, Mallaret M, Micallef J, Ponté C, Roussin A, **Lapeyre-Mestre M**. [Comment on: "Social Media Mining for Toxicovigilance: Automatic Monitoring of Prescription Medication Abuse from Twitter"](#). *Drug Saf*. 2017 Feb;40(2):183-185. doi: 10.1007/s40264-016-0497-7.
7. Jouanjus E, Raymond V, **Lapeyre-Mestre M**, Wolff V. [What is the Current Knowledge About the Cardiovascular Risk for Users of Cannabis-Based Products? A Systematic Review](#). *Curr Atheroscler Rep*. 2017 Jun;19(6):26. doi: 10.1007/s11883-017-0663-0.
8. Mezaache S, Derumeaux H, Ferraro P, Capdepon P, Steinbach JC, Abballe X, Palas D, Saichi N, Desboeuf K, **Lapeyre-Mestre M**, Sailler L, Moulis G. [Validation of an algorithm identifying incident primary immune thrombocytopenia in the French national health insurance database](#). *Eur J Haematol*. 2017 Oct;99(4):344-349. doi: 10.1111/ejh.12926.
9. Moulis G, Germain J, Comont T, Brun N, Dingremont C, Castel B, Arista S, Sailler L, **Lapeyre-Mestre M**, Beyne-Rauzy O, Godeau B, Adoue D; CARMEN Investigators Group. [Newly diagnosed immune thrombocytopenia adults: Clinical epidemiology, exposure to treatments, and evolution. Results of the](#)

- [CARMEN multicenter prospective cohort](#). Am J Hematol. 2017 Jun;92(6):493-500. doi: 10.1002/ajh.24702.
10. Moulis G, **Lapeyre-Mestre M**, Adoue D, Sailler L. [\[Epidemiology and pharmacoepidemiology of immune thrombocytopenia\]](#). Rev Med Interne. 2017 Jul;38(7):444-449. doi: 10.1016/j.revmed.2016.12.016.
  11. Moulis G, **Lapeyre-Mestre M**, Palmaro A, Sailler L. [Infections in non-splenectomized persistent or chronic primary immune thrombocytopenia adults: risk factors and vaccination effect](#). J Thromb Haemost. 2017 Apr;15(4):785-791. doi: 10.1111/jth.13622.
  12. Nguyen TT, Pariente A, Montastruc JL, **Lapeyre-Mestre M**, Rousseau V, Rascol O, Bégaud B, Montastruc F. [An original pharmacoepidemiologic - pharmacodynamic method: application to antipsychotic-induced movement disorders](#). Br J Clin Pharmacol. 2017 Mar;83(3):612-622. doi: 10.1111/bcp.13145.
  13. Palmaro A, Boucherie Q, Dupouy J, Micallef J, **Lapeyre-Mestre M**. [Immeasurable time bias due to hospitalization in medico-administrative databases: which impact for pharmacoepidemiological studies?](#) Pharmacoepidemiol Drug Saf. 2017 May;26(5):544-553. doi: 10.1002/pds.4193.
  14. Palmaro A, Gauthier M, Conte C, Grosclaude P, Despas F, **Lapeyre-Mestre M**. [Identifying multiple myeloma patients using data from the French health insurance databases: Validation using a cancer registry](#). Medicine (Baltimore). 2017 Mar;96(12):e6189. doi: 10.1097/MD.00000000000006189.
  15. Palmaro A, Gauthier M, Despas F, **Lapeyre-Mestre M**. [Identifying cancer drug regimens in French health insurance database: An application in multiple myeloma patients](#). Pharmacoepidemiol Drug Saf. 2017 Dec;26(12):1492-1499. doi: 10.1002/pds.4266.
  16. Palmaro A, Rougé-Bugat ME, Gauthier M, Despas F, Moulis G, **Lapeyre-Mestre M**. [Real-life practices for preventing venous thromboembolism in multiple myeloma patients: a cohort study from the French health insurance database](#). Pharmacoepidemiol Drug Saf. 2017 May;26(5):578-586. doi: 10.1002/pds.4180.
  17. Patras de Campaigno E, Bondon-Guitton E, Laurent G, Montastruc F, Montastruc JL, **Lapeyre-Mestre M**, Despas F. [Identification of cellular targets involved in cardiac failure caused by PK1 in oncology: an approach combining pharmacovigilance and pharmacodynamics](#). Br J Clin Pharmacol. 2017 Jul;83(7):1544-1555. doi: 10.1111/bcp.13238.
  18. Pastras de Campaigno E, Kebir I, Montastruc JL, Rueter M, Maret D, **Lapeyre-Mestre M**, Sallerin B, Despas F. [Drug-Induced Dental Caries: A Disproportionality Analysis Using Data from VigiBase](#). Drug Saf. 2017 Dec;40(12):1249-1258. doi: 10.1007/s40264-017-0575-5.
  19. Ponté C, **Lapeyre-Mestre M**. [\[Psychoactive effects of 'legal high': About lysergic acid amide \(LSA\)\]](#). Therapie. 2017 Oct;72(5):605-608. doi: 10.1016/j.therap.2017.01.012.
  20. Ponté C, Pi C, Palmaro A, Jouanjus E, **Lapeyre-Mestre M**; French Addictovigilance Network. [Early signal of diverted use of tropicamide eye drops in France](#). Br J Clin Pharmacol. 2017 Aug;83(8):1791-1800. doi: 10.1111/bcp.13272.
  21. Récoché I, Lebaudy C, Cool C, Sourdet S, Piau A, **Lapeyre-Mestre M**, Vellas B, Cestac P. [Potentially inappropriate prescribing in a population of frail elderly people](#). Int J Clin Pharm. 2017 Feb;39(1):113-119. doi: 10.1007/s11096-016-0406-2.
  22. Rolland B, Auffret M, Labreuche J, **Lapeyre-Mestre M**, Dib M, Kemkem A, Grit I, Drelon M, Duhamel A, Cabe N, Vabret F, Guillin O, Bagnuet A, Masquelier C, Dervaux A, Deheul S, Bordet R, Carton L, Cottencin O, Jardri R, Gautier S. [Phone-based safety monitoring of the first year of baclofen treatment for alcohol use disorder: the BACLOPHONE cohort study protocol](#). Expert Opin Drug Saf. 2017 Feb;16(2):125-132. doi: 10.1080/14740338.2017.1270939.

23. Sommet A, **Lapeyre-Mestre M**. [Drug Use and Mortality in Parkinson Disease](#). J Am Med Dir Assoc. 2017 Nov 1;18(11):989. doi: 10.1016/j.jamda.2017.07.015.
24. Thu Trang D, Cool C, Laffon de Mazieres C, **Lapeyre-Mestre M**, Montastruc JL, Rascol O, Rolland Y, Sommet A. [Mortality and Antipsychotic Drug Use in Elderly Patients With Parkinson Disease in Nursing Homes](#). J Am Med Dir Assoc. 2017 Sep 1;18(9):791-796. doi: 10.1016/j.jamda.2017.04.014.

#### 2016

1. Bossard JB, Ponté C, Dupouy J, **Lapeyre-Mestre M**, Jouanjus E. [Disproportionality Analysis for the Assessment of Abuse and Dependence Potential of Pregabalin in the French Pharmacovigilance Database](#). Clin Drug Investig. 2016 Sep;36(9):735-742. doi: 10.1007/s40261-016-0421-z.
2. Breu-Dejean N, Driot D, Dupouy J, **Lapeyre-Mestre M**, Rostaing L. [Efficacy of Psychoeducational Intervention on Allograft Function in Kidney Transplant Patients: 10-Year Results of a Prospective Randomized Study](#). Exp Clin Transplant. 2016 Feb;14(1):38-44.
3. Cailhol L, Francois M, Thalamas C, Garrido C, Birmes P, Pourcel L, **Lapeyre-Mestre M**, Paris J. [Is borderline personality disorder only a mental health problem?](#) Personal Ment Health. 2016 Nov;10(4):328-336. doi: 10.1002/pmh.1350.
4. Conte C, Rueter M, Laurent G, Bourrel R, **Lapeyre-Mestre M**, Despas F. [Psychotropic drug initiation during the first diagnosis and the active treatment phase of B cell non-Hodgkin's lymphoma: a cohort study of the French national health insurance database](#). Support Care Cancer. 2016 Nov;24(11):4791-9. doi: 10.1007/s00520-016-3331-y.
5. de Souto Barreto P, **Lapeyre-Mestre M**, Cestac P, Vellas B, Rolland Y. [Effects of a geriatric intervention aiming to improve quality care in nursing homes on benzodiazepine use and discontinuation](#). Br J Clin Pharmacol. 2016 Apr;81(4):759-67. doi: 10.1111/bcp.12847.
6. Driot D, Chicoulaa B, Jouanjus E, Dupouy J, Oustric S, **Lapeyre-Mestre M**. [Pregabalin use disorder and secondary nicotine dependence in a woman with no substance abuse history](#). Therapie. 2016 Dec;71(6):575-578. doi: 10.1016/j.therap.2016.04.006.
7. ESUB-MG Study Group. (**Lapeyre-Mestre M** collaborator) [Study protocol of the ESUB-MG cluster randomized trial: a pragmatic trial assessing the implementation of urine drug screening in general practice for buprenorphine maintained patients](#). BMC Fam Pract. 2016 Mar 1;17:24. doi: 10.1186/s12875-016-0413-3.
8. **Lapeyre-Mestre M**. [A Review of Adverse Outcomes Associated with Psychoactive Drug Use in Nursing Home Residents with Dementia](#). Drugs Aging. 2016 Dec;33(12):865-888.
9. Moulis G, Audemard-Verger A, Arnaud L, Luxembourger C, Montastruc F, Gaman AM, Svenungsson E, Ruggeri M, Mahévas M, Gerfaud-Valentin M, Brainsky A, Michel M, Godeau B, **Lapeyre-Mestre M**, Sailler L. [Risk of thrombosis in patients with primary immune thrombocytopenia and antiphospholipid antibodies: A systematic review and meta-analysis](#). Autoimmun Rev. 2016 Mar;15(3):203-9. doi: 10.1016/j.autrev.2015.11.001.
10. Moulis G, Germain J, Adoue D, Beyne-Rauzy O, Derumeaux H, Sailler L, **Lapeyre-Mestre M**. [Validation of immune thrombocytopenia diagnosis code in the French hospital electronic database](#). Eur J Intern Med. 2016 Jul;32:e21-2. doi: 10.1016/j.ejim.2016.02.021.
11. Palmaro A, Moulis G, Despas F, Dupouy J, **Lapeyre-Mestre M**. [Overview of drug data within French health insurance databases and implications for pharmacoepidemiological studies](#). Fundam Clin Pharmacol. 2016 Jun 28. doi: 10.1111/fcp.12214.

12. Pugnet G, Sailler L, Fournier JP, Bourrel R, Montastruc JL, **Lapeyre-Mestre M**. [Predictors of Cardiovascular Hospitalization in Giant Cell Arteritis: Effect of Statin Exposure. A French Population-based Study](#). J Rheumatol. 2016 Dec;43(12):2162-2170.
13. Récoché I, Rousseau V, Bourrel R, **Lapeyre-Mestre M**, Chebane L, Despas F, Montastruc JL, Bondon-Guitton E. [Drug-drug interactions with imatinib: An observational study](#). Medicine (Baltimore). 2016 Oct;95(40):e5076.
14. Sahli L, **Lapeyre-Mestre M**, Derumeaux H, Moulis G. [Positive predictive values of selected hospital discharge diagnoses to identify infections responsible for hospitalization in the French national hospital database](#). Pharmacoepidemiol Drug Saf. 2016 Jul;25(7):785-9. doi: 10.1002/pds.4006.

#### 2015

1. Barreto Pde S, Demougeot L, Pillard F, **Lapeyre-Mestre M**, Rolland Y. [Exercise training for managing behavioral and psychological symptoms in people with dementia: A systematic review and meta-analysis](#). Ageing Res Rev. 2015 Nov;24(Pt B):274-85. doi: 10.1016/j.arr.2015.09.001.
2. Cailhol L, Thalamas C, Garrido C, Birmes P, **Lapeyre-Mestre M**. [\[Mental health service utilization among borderline personality disorder patients inpatient\]](#). Encephale. 2015 Apr;41(2):115-22. doi: 10.1016/j.encep.2014.10.008.
3. Caillet C, Sichanh C, Syhakhang L, Delpierre C, Manithip C, Mayxay M, **Lapeyre-Mestre M**, Newton PN, Roussin A. [Population awareness of risks related to medicinal product use in Vientiane Capital, Lao PDR: a cross-sectional study for public health improvement in low and middle income countries](#). BMC Public Health. 2015 Jun 27;15:590. doi: 10.1186/s12889-015-1948-2.
4. Carton L, Cottencin O, **Lapeyre-Mestre M**, Geoffroy PA, Favre J, Simon N, Bordet R, Rolland B. [Off-Label Prescribing of Antipsychotics in Adults, Children and Elderly Individuals: A Systematic Review of Recent Prescription Trends](#). Curr Pharm Des. 2015;21(23):3280-97.
5. Compaci G, Rueter M, Lamy S, Oberic L, Recher C, **Lapeyre-Mestre M**, Laurent G, Despas F. [Ambulatory Medical Assistance--After Cancer \(AMA-AC\): A model for an early trajectory survivorship survey of lymphoma patients treated with anthracycline-based chemotherapy](#). BMC Cancer. 2015 Oct 24;15:781. doi: 10.1186/s12885-015-1815-7.
6. Gallini A, Gardette V, **Lapeyre-Mestre M**, de Souto Barreto P, Vellas B, Andrieu S, Rolland Y. [Dementia Diagnosis and Influenza Vaccination in French Nursing Home Residents](#). J Am Geriatr Soc. 2015 Jun;63(6):1256-8. doi: 10.1111/jgs.13515.
7. Laconi S, Cailhol L, Pourcel L, Thalamas C, **Lapeyre-Mestre M**, Chabrol H. [\[Relationship between defense mechanism and therapeutic alliance\]](#). Encephale. 2015 Oct;41(5):429-34. doi: 10.1016/j.encep.2014.10.021.
8. Laffon de Mazières C, **Lapeyre-Mestre M**, Vellas B, de Souto Barreto P, Rolland Y. [Organizational Factors Associated With Inappropriate Neuroleptic Drug Prescribing in Nursing Homes: A Multilevel Approach](#). J Am Med Dir Assoc. 2015 Jul 1;16(7):590-7. doi: 10.1016/j.jamda.2015.01.092.
9. **Lapeyre-Mestre M**, Dupui M. [Drug abuse monitoring: which pharmacoepidemiological resources at the European level?](#) Therapie. 2015 Mar-Apr;70(2):147-65. doi: 10.2515/therapie/2015010.
10. Micallef J, Frauger E, Palmaro A, Boucherie Q, Lapeyre Mestres M. [Example of an investigation of an "emergent" phenomenon in addiction vigilance: the case of methylphenidate](#). Therapie. 2015 Mar-Apr;70(2):191-202. doi: 10.2515/therapie/2015013.
11. Micallef J, **Lapeyre-Mestre M**. [\[Addictovigilance: the pharmacological challenge of assessment and prevention of risky substances\]](#). Therapie. 2015 Mar-Apr;70(2):111. doi: 10.2515/therapie/2015017.



12. Montastruc F, Palmaro A, Bagheri H, Schmitt L, Montastruc JL, **Lapeyre-Mestre M**. [Role of serotonin 5-HT<sub>2C</sub> and histamine H<sub>1</sub> receptors in antipsychotic-induced diabetes: A pharmacoepidemiological-pharmacodynamic study in VigiBase](#). Eur Neuropsychopharmacol. 2015 Oct;25(10):1556-65. doi: 10.1016/j.euroneuro.2015.07.010.
13. Moulis F, Moulis G, Balardy L, Gérard S, Montastruc F, Sourdet S, Rougé-Bugat ME, **Lapeyre-Mestre M**, Montastruc JL, Rolland Y, Vellas B. [Exposure to atropinic drugs and frailty status](#). J Am Med Dir Assoc. 2015 Mar;16(3):253-7. doi: 10.1016/j.jamda.2014.11.017.
14. Moulis F, Moulis G, Balardy L, Gérard S, Sourdet S, Rougé-Bugat ME, **Lapeyre-Mestre M**, Montastruc JL, Rolland Y, Vellas B. [Searching for a polypharmacy threshold associated with frailty](#). J Am Med Dir Assoc. 2015 Mar;16(3):259-61. doi: 10.1016/j.jamda.2014.11.016.
15. Moulis G, **Lapeyre-Mestre M**, Mahévas M, Montastruc JL, Sailler L. [Need for an improved vaccination rate in primary immune thrombocytopenia patients exposed to rituximab or splenectomy. A nationwide population-based study in France](#). Am J Hematol. 2015 Apr;90(4):301-5. doi: 10.1002/ajh.23930.
16. Moulis G, **Lapeyre-Mestre M**, Montastruc JL, Sailler L. [Exposure to non-corticosteroid treatments in adult primary immune thrombocytopenia before the chronic phase in the era of thrombopoietin receptor agonists in France. A nationwide population-based study](#). Autoimmun Rev. 2015 Feb;14(2):168-73. doi: 10.1016/j.autrev.2014.10.017.
17. Moulis G, **Lapeyre-Mestre M**, Palmaro A, Pugnet G, Montastruc JL, Sailler L. [French health insurance databases: What interest for medical research?](#) Rev Med Interne. 2015 Jun;36(6):411-7. doi: 10.1016/j.revmed.2014.11.009.
18. Moulis G, Palmaro A, Sailler L, **Lapeyre-Mestre M**. [Corticosteroid Risk Function of Severe Infection in Primary Immune Thrombocytopenia Adults. A Nationwide Nested Case-Control Study](#). PLoS One. 2015 Nov 11;10(11):e0142217. doi: 10.1371/journal.pone.0142217.
19. Moulis G, Sailler L, **Lapeyre-Mestre M**. [Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic review: comment](#). J Thromb Haemost. 2015 Aug;13(8):1521-2. doi: 10.1111/jth.12984.
20. Nguyen TT, Palmaro A, Montastruc F, **Lapeyre-Mestre M**, Moulis G. [Signal for Thrombosis with Eltrombopag and Romiplostim: A Disproportionality Analysis of Spontaneous Reports Within VigiBase®](#). Drug Saf. 2015 Dec;38(12):1179-86. doi: 10.1007/s40264-015-0337-1.
21. Palmaro A, Bissuel R, Renaud N, Durrieu G, Escourrou B, Oustric S, Montastruc JL, **Lapeyre-Mestre M**. [Off-label prescribing in pediatric outpatients](#). Pediatrics. 2015 Jan;135(1):49-58. doi: 10.1542/peds.2014-0764.
22. Palmaro A, Dupouy J, **Lapeyre-Mestre M**. [Benzodiazepines and risk of death: Results from two large cohort studies in France and UK](#). Eur Neuropsychopharmacol. 2015 Oct;25(10):1566-77. doi: 10.1016/j.euroneuro.2015.07.006.
23. Pauly V, **Lapeyre-Mestre M**, Braunstein D, Rueter M, Thirion X, Jouanjus E, Micallef J. [Is statin exposure associated with occurrence or better outcome in giant cell arteritis? Results from a French population-based study](#). J Rheumatol. 2015 Feb;42(2):316-22. doi: 10.3899/jrheum.140906.
24. Rouge-Bugat ME, Lassoued D, Bacrie J, Boussier N, Delord JP, Oustric S, Bauvin E, **Lapeyre-Mestre M**, Bertucci F, Grosclaude P. [Guideline sheets on the side effects of anticancer drugs are useful for general practitioners](#). Support Care Cancer. 2015 Dec;23(12):3473-80. doi: 10.1007/s00520-015-2705-x.

25. Roulet L, Ballereau F, **Lapeyre-Mestre M**, Joris-Frasseren M, Asseray N. [\[Developing a terminology in the French language for clinical practice and research in drug safety\]](#). Therapie. 2015 May-Jun;70(3):283-92. doi: 10.2515/therapie/2014215.